Drug
Trastuzumab deruxtecan clinical trials
Also written Enhertu, DS-8201a and DS-8201.
- studies test it
- 123
- open now
- 76
- in phase 3
- 23
- first study started
- 2015
Keep track of what changes. Save the trastuzumab deruxtecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
121 studies that test it; most in 2026 (23); 2 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 2 |
| 2020 | 10 |
| 2021 | 12 |
| 2022 | 5 |
| 2023 | 14 |
| 2024 | 19 |
| 2025 | 21 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 31
- Phase 2
- 76
- Phase 3
- 23
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 50 · Other 73
Daiichi Sankyo (21) · AstraZeneca (16) · National Cancer Institute (NCI) (9) · Fudan University (8) · Daiichi Sankyo Co., Ltd. (5) · MedSIR (4) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (3)
Often tested with
Tested in the same studies.
Sacituzumab govitecan (9) · Trastuzumab (6) · Capecitabine (5) · Nivolumab (5) · Tucatinib (5) · Pertuzumab (4) · Oxaliplatin (4) · Pembrolizumab (4)
Studies
Open first, then newest update. How each study uses trastuzumab deruxtecan is read from its arms, and is right about nine times in ten.
Testing it · 123
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06899126Written as Trastuzumab Deruxtecan
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Written as Trastuzumab Deruxtecan
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT07619521Written as Trastuzumab Deruxtecan
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214Written as Trastuzumab Deruxtecan
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875Written as Trastuzumab deruxtecan
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT07137416Written as Trastuzumab Deruxtecan
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as Trastuzumab Deruxtecan (T-DXd)
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754Written as Trastuzumab deruxtecan
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Trastuzumab deruxtecan
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357Written as Trastuzumab deruxtecan
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingPhase 2National Cancer Institute (NCI)NCT04616560Written as Trastuzumab Deruxtecan
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112Written as Trastuzumab deruxtecan
- TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingPhase 2Filipa Lynce, MDNCT05795101Written as Trastuzumab deruxtecan
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Trastuzumab Deruxtecan
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614Written as Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNot yet recruitingPhase 1Baptist Health South FloridaNCT07454668Written as Trastuzumab Deruxtecan
- A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07691489Written as Fam-Trastuzumab Deruxtecan-Nxki
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Written as Fam-Trastuzumab Deruxtecan-Nxki
- A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingPhase 2Fujian Medical UniversityNCT07836257Written as Trastuzumab Deruxtecan (T-DXd)
- Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07619365Written as Trastuzumab deruxtecan
See all 123 studies that test trastuzumab deruxtecan →
Given in every arm · 20 — trastuzumab deruxtecan is usual care beside what is tested
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1Daiichi SankyoNCT05765851Written as T-DXd
- Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab DeruxtecanNot yet recruitingPhase 3Mario Negri Institute for Pharmacological ResearchNCT07828054Written as T-DXd
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT06364410Written as Trastuzumab Deruxtecan
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Trastuzumab deruxtecan
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingPhase 3SWOG Cancer Research NetworkNCT07578116Written as Trastuzumab Deruxtecan
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05417594Written as Trastuzumab Deruxtecan (T-DXd)
- A Study of PHST001 in Advanced Solid TumorsRecruitingPhase 1Pheast TherapeuticsNCT06840886Written as Trastuzumab Deruxtecan
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Daiichi SankyoNCT07701941Written as Trastuzumab deruxtecan
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07152782Written as Trastuzumab Deruxtecan
- T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07150208Written as Trastuzumab Deruxtecan (T-DXd)
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingPhase 1Eli Lilly and CompanyNCT05614739Written as Trastuzumab Deruxtecan
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingPhase 1AstraZenecaNCT04686305Written as T-DXd
- Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT04553770Written as Trastuzumab Deruxtecan
- A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsActive, not recruitingPhase 2AstraZenecaNCT06271837Written as Trastuzumab deruxtecan
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Written as Trastuzumab deruxtecan
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingPhase 1AstraZenecaNCT04556773Written as Trastuzumab deruxtecan
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingPhase 1/2FBD Biologics LimitedNCT06771622Written as Trastuzumab deruxtecan
- A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT04538742Written as Trastuzumab deruxtecan
- ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruitingPhase 1Enliven TherapeuticsNCT05650879Written as Fam-Trastuzumab Deruxtecan-Nxki
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedPhase 1/2Silverback TherapeuticsNCT05091528Written as trastuzumab deruxtecan
As the comparator · 7 — what is tested is compared with trastuzumab deruxtecan
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Trastuzumab deruxtecan
- A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07678957Written as DS-8201
- Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07630103Written as Trastuzumab Deruxtecan for Injection (T-DXd)
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07294508Written as T-Dxd + Pertuzumab
- Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07416253Written as Trastuzumab deruxtecan
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07417241Written as T-DXd
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824Written as Trastuzumab deruxtecan
Codes
What other systems call trastuzumab deruxtecan · ClinicalTrials.gg INT000605
- MeSH (NLM) C000614160trastuzumab deruxtecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5384HK7574TRASTUZUMAB DERUXTECANConfirmed FDA, NLM, Wikidata
- RxNorm 2267582One source FDA
- Wikidata Q80109553trastuzumab deruxtecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C128799Trastuzumab DeruxtecanOne source FDA
- DrugBank DB14962One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614160 | trastuzumab deruxtecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5384HK7574 | TRASTUZUMAB DERUXTECAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2267582 | — | One source FDA |
| Wikidata | Q80109553 | trastuzumab deruxtecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C128799 | Trastuzumab Deruxtecan | One source FDA |
| DrugBank | DB14962 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.